Q3 EPS Estimates for Spruce Biosciences Cut by HC Wainwright

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Spruce Biosciences in a report released on Wednesday, August 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($5.13) per share for the quarter, down from their previous estimate of ($4.81). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($25.14) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2026 earnings at ($4.38) EPS, FY2026 earnings at ($23.32) EPS, Q1 2027 earnings at ($3.68) EPS, Q2 2027 earnings at ($3.37) EPS, Q3 2027 earnings at ($2.13) EPS and FY2027 earnings at ($8.52) EPS.

Spruce Biosciences (NASDAQ:SPRB) last posted its earnings results on Wednesday, August 12th. The company reported ($6.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.79) by ($0.89).

Several other equities analysts have also weighed in on SPRB. The Goldman Sachs Group upgraded Spruce Biosciences to an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings downgraded Spruce Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 12th. Citizens Jmp dropped their price target on shares of Spruce Biosciences from $150.00 to $144.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 13th. Guggenheim reissued a “buy” rating and issued a $104.00 price target (down from $123.00) on shares of Spruce Biosciences in a report on Monday, August 17th. Finally, B. Riley Financial assumed coverage on shares of Spruce Biosciences in a research report on Monday, July 13th. They set a “buy” rating and a $160.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $159.50.

Spruce Biosciences Stock Up 3.0%

SPRB opened at $63.30 on Friday. The company has a fifty day moving average of $49.66 and a two-hundred day moving average of $55.45. The stock has a market capitalization of $181.67 million, a price-to-earnings ratio of -1.59 and a beta of 3.23. Spruce Biosciences has a fifty-two week low of $7.00 and a fifty-two week high of $240.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.23 and a current ratio of 9.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. acquired a new stake in Spruce Biosciences during the second quarter worth about $7,937,000. Ikarian Capital LLC increased its holdings in shares of Spruce Biosciences by 810.3% during the 4th quarter. Ikarian Capital LLC now owns 121,356 shares of the company’s stock worth $10,571,000 after buying an additional 108,024 shares during the last quarter. Squadron Capital Management LLC purchased a new stake in shares of Spruce Biosciences during the 4th quarter valued at approximately $6,098,000. Wellington Management Group LLP acquired a new position in Spruce Biosciences in the fourth quarter valued at approximately $5,135,000. Finally, ADAR1 Capital Management LLC purchased a new position in Spruce Biosciences in the fourth quarter worth approximately $5,052,000. Institutional investors and hedge funds own 91.71% of the company’s stock.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.